The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...

Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

"Biogen's anticompetitive conduct, and the PBMs' participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell ...

(Reuters) - Biogen Idec Inc said on Tuesday it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera until 2028. The new patent covers ...

Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec is certainly hoping so. The biotech's multiple sclerosis drug Tecfidera received a positive ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...

A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera®. The drug is the most widely prescribed ...

Three lawsuits allege Biogen Inc. forces multiple sclerosis patients to overpay for their medication. Baltimore city officials and other plaintiffs accuse Biogen of monopolizing the MS drug market.